Padraig Mcdonnell Sells 911 Shares of Agilent Technologies (NYSE:A) Stock

Agilent Technologies, Inc. (NYSE:A) CEO Padraig Mcdonnell sold 911 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $143.24, for a total transaction of $130,491.64. Following the transaction, the chief executive officer owned 32,058 shares in the company, valued at $4,591,987.92. This represents a 2.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Padraig Mcdonnell also recently made the following trade(s):

• On Wednesday, November 12th, Padraig Mcdonnell sold 12,490 shares of Agilent Technologies stock. The stock was sold at an average price of $150.00, for a total value of $1,873,500.00.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $151.49 on Friday. The stock has a fifty day moving average price of $139.65 and a two-hundred day moving average price of $125.10. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The firm has a market cap of $42.95 billion, a P/E ratio of 35.56, a PEG ratio of 4.67 and a beta of 1.29. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $153.84.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts’ consensus estimates of $1.37. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Research analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Investors of record on Tuesday, January 6th will be paid a dividend of $0.255 per share. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.25. This represents a $1.02 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, January 6th. Agilent Technologies’s dividend payout ratio (DPR) is currently 23.94%.

Institutional Trading of Agilent Technologies

Several hedge funds and other institutional investors have recently modified their holdings of A. Flynn Zito Capital Management LLC lifted its stake in Agilent Technologies by 3.2% in the 3rd quarter. Flynn Zito Capital Management LLC now owns 2,257 shares of the medical research company’s stock worth $290,000 after acquiring an additional 69 shares in the last quarter. Forum Financial Management LP lifted its position in shares of Agilent Technologies by 2.5% in the third quarter. Forum Financial Management LP now owns 2,921 shares of the medical research company’s stock worth $375,000 after purchasing an additional 70 shares in the last quarter. Gabelli Funds LLC boosted its holdings in shares of Agilent Technologies by 1.1% during the third quarter. Gabelli Funds LLC now owns 6,620 shares of the medical research company’s stock worth $850,000 after purchasing an additional 74 shares during the period. Fiduciary Trust Co boosted its position in Agilent Technologies by 1.6% during the third quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock valued at $633,000 after purchasing an additional 77 shares during the last quarter. Finally, Wedmont Private Capital boosted its position in Agilent Technologies by 2.3% during the third quarter. Wedmont Private Capital now owns 3,630 shares of the medical research company’s stock valued at $503,000 after purchasing an additional 81 shares during the last quarter. Institutional investors and hedge funds own 87.41% of the company’s stock.

Wall Street Analyst Weigh In

A has been the topic of several recent research reports. Wall Street Zen upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Robert W. Baird raised their price objective on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, August 28th. Rothschild & Co Redburn started coverage on Agilent Technologies in a report on Wednesday, October 8th. They issued a “buy” rating and a $165.00 target price on the stock. Rothschild Redb raised Agilent Technologies to a “strong-buy” rating in a report on Wednesday, October 8th. Finally, Evercore ISI increased their price target on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a research report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $149.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.